Fibroblast growth factors (FGFs) are in clinical trials as therapies for a variety of ischemic vascular disorders. However, their short in vivo half-lives could make it difficult to maintain therapeutic levels without frequent injections. This problem has prompted Ballinger et al. to search for more stable small-molecule mimetics to replace FGF (p. 1199). Using a combination of phage display and rational design, they engineered a peptide with no homology to FGF that binds to the FGF receptor and potently reproduces FGF's biological effects (see also pp. 1157–1158).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeWitt, N. A synthetic FGF agonist. Nat Biotechnol 17, 1150 (1999). https://doi.org/10.1038/70681
Issue Date:
DOI: https://doi.org/10.1038/70681